Skip to main content
Figure 5 | Orphanet Journal of Rare Diseases

Figure 5

From: Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)

Figure 5

In IVS4 + 919G > A Fabry disease patients, the baseline and last follow-up LVMI (A)(C) as well as baseline, first and last follow-up serum lyso-Gb3 results (B)(D) were shown in mean ± SD. There were significant decreased of LVMI between baseline and last follow-up in IVS4 + 919G > A male (A) and female (C) FD patients. Significant decreased in serum lyso-Gb3 between baseline and first follow-up results were also found in IVS4 + 919G > A male (B) and female (D) patients. However, there were no statistical significance between baseline and last follow-up serum lyso-Gb3 results in IVS4 + 919G > A male (B) or female (D) FD patients. FD: Fabry disease; LVMI: left ventricular mass index; lyso-Gb3: globotriaosylsphingosine; SD: standard deviation.

Back to article page